| Clinical data | ||
| Age (years) | 68 | [60–71] |
| Gender (male) | 11 | (65) |
| Diagnosis DCM (others ICM) | 15 | (88) |
| Co-morbidities | ||
| BMI (kg/m2) | 31 | [28–35] |
| Arterial hypertension | 14 | (82) |
| Diabetes mellitus type 2 | 7 | (41) |
| Previous ICD therapy | 5 | (29) |
| Medication | ||
| Beta blocker | 16 | (94) |
| ACE inhibitor | 8 | (47) |
| AT receptor blocker | 8 | (47) |
| Diuretics | 17 | (100) |
| Aldosterone antagonist | 14 | (82) |
| Cardiac data | ||
| Sinus rhythm | 17 | (100) |
| Heart rate (b.p.m.) | 74 | [64–81] |
| Intrinsic QRS width (ms) | 140 | [120–150] |
| LBBB | 16 | (94) |
| CRT device data | ||
| Type of device (ICD) | 17 | (100) |
| Stimulation rate (%) | 99 | [98–100] |
| VV-delay programming (LV > RV) | 20 | [0–40] |
| Clinical data | ||
| Age (years) | 68 | [60–71] |
| Gender (male) | 11 | (65) |
| Diagnosis DCM (others ICM) | 15 | (88) |
| Co-morbidities | ||
| BMI (kg/m2) | 31 | [28–35] |
| Arterial hypertension | 14 | (82) |
| Diabetes mellitus type 2 | 7 | (41) |
| Previous ICD therapy | 5 | (29) |
| Medication | ||
| Beta blocker | 16 | (94) |
| ACE inhibitor | 8 | (47) |
| AT receptor blocker | 8 | (47) |
| Diuretics | 17 | (100) |
| Aldosterone antagonist | 14 | (82) |
| Cardiac data | ||
| Sinus rhythm | 17 | (100) |
| Heart rate (b.p.m.) | 74 | [64–81] |
| Intrinsic QRS width (ms) | 140 | [120–150] |
| LBBB | 16 | (94) |
| CRT device data | ||
| Type of device (ICD) | 17 | (100) |
| Stimulation rate (%) | 99 | [98–100] |
| VV-delay programming (LV > RV) | 20 | [0–40] |
Continuous data are given as median [interquartile range]. Categorial data are given as number (percentage) of patients.
ACE, angiotensin converting enzyme; AT, angiotensinogen; BMI, body mass index; CRT, cardiac resynchronization therapy; LV, left ventricular; DCM, dilative cardiomyopathy; ICD, intra-cardiac defibrillator; ICM, ischaemic cardiomyopathy; LBBB, left bundle branch block; RV, right ventricular; VV, interventricular.
| Clinical data | ||
| Age (years) | 68 | [60–71] |
| Gender (male) | 11 | (65) |
| Diagnosis DCM (others ICM) | 15 | (88) |
| Co-morbidities | ||
| BMI (kg/m2) | 31 | [28–35] |
| Arterial hypertension | 14 | (82) |
| Diabetes mellitus type 2 | 7 | (41) |
| Previous ICD therapy | 5 | (29) |
| Medication | ||
| Beta blocker | 16 | (94) |
| ACE inhibitor | 8 | (47) |
| AT receptor blocker | 8 | (47) |
| Diuretics | 17 | (100) |
| Aldosterone antagonist | 14 | (82) |
| Cardiac data | ||
| Sinus rhythm | 17 | (100) |
| Heart rate (b.p.m.) | 74 | [64–81] |
| Intrinsic QRS width (ms) | 140 | [120–150] |
| LBBB | 16 | (94) |
| CRT device data | ||
| Type of device (ICD) | 17 | (100) |
| Stimulation rate (%) | 99 | [98–100] |
| VV-delay programming (LV > RV) | 20 | [0–40] |
| Clinical data | ||
| Age (years) | 68 | [60–71] |
| Gender (male) | 11 | (65) |
| Diagnosis DCM (others ICM) | 15 | (88) |
| Co-morbidities | ||
| BMI (kg/m2) | 31 | [28–35] |
| Arterial hypertension | 14 | (82) |
| Diabetes mellitus type 2 | 7 | (41) |
| Previous ICD therapy | 5 | (29) |
| Medication | ||
| Beta blocker | 16 | (94) |
| ACE inhibitor | 8 | (47) |
| AT receptor blocker | 8 | (47) |
| Diuretics | 17 | (100) |
| Aldosterone antagonist | 14 | (82) |
| Cardiac data | ||
| Sinus rhythm | 17 | (100) |
| Heart rate (b.p.m.) | 74 | [64–81] |
| Intrinsic QRS width (ms) | 140 | [120–150] |
| LBBB | 16 | (94) |
| CRT device data | ||
| Type of device (ICD) | 17 | (100) |
| Stimulation rate (%) | 99 | [98–100] |
| VV-delay programming (LV > RV) | 20 | [0–40] |
Continuous data are given as median [interquartile range]. Categorial data are given as number (percentage) of patients.
ACE, angiotensin converting enzyme; AT, angiotensinogen; BMI, body mass index; CRT, cardiac resynchronization therapy; LV, left ventricular; DCM, dilative cardiomyopathy; ICD, intra-cardiac defibrillator; ICM, ischaemic cardiomyopathy; LBBB, left bundle branch block; RV, right ventricular; VV, interventricular.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
